KQ 2206
Alternative Names: KQ-2206Latest Information Update: 24 May 2024
At a glance
- Originator Novatim Immune Therapeutics (Zhejiang)
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Renal cancer
Most Recent Events
- 05 Apr 2024 Preclinical trials in Renal cancer in China (IV) (Novatim Immune Therapeutics pipeline, April 2024)